The passage below is from a Cbio statement on 12 Oct 2011:
"The delivery of the final report and completed workplan to Novo Nordisk will trigger an immediate positive Cbio balance sheet change. A US$3 million option fee already recieved from Novo Nordisk has up until now been accounted for an unearned income (and a liability). however this amount will now be earned by Cbio and considered income in the current financial year."
I didn't notice any mention of it in the recent appendix 4C
Correct me if I'm wrong....
CBZ Price at posting:
8.7¢ Sentiment: Hold Disclosure: Held
